Akebia Therapeutics

AKBA · NASDAQ

$0.6181−$0.062 (−9.12%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $0.6801

Latest news

Press releaseSep 14, 8:00 AM ETGlobe Newswire
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
NewsAug 6, 1:06 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsAug 6, 8:06 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
NewsAug 6, 8:04 AM ETAvi Kapoor
Western Digital, Applovin, Zillow Group And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
NewsAug 5, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseAug 5, 4:05 PM ETGlobe Newswire
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Press releaseAug 3, 8:00 AM ETGlobe Newswire
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
Press releaseJun 30, 8:00 AM ETGlobe Newswire
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
Press releaseJun 10, 8:00 AM ETGlobe Newswire
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
NewsMay 7, 7:05 AM ET
Akebia Therapeutics Q1 EPS $(0.03), Inline, Sales $53.544M Beat $51.668M Estimate
Press releaseMay 7, 7:00 AM ETGlobe Newswire
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
Press releaseMay 4, 8:00 AM ETGlobe Newswire
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology
Press releaseApr 13, 8:00 AM ETGlobe Newswire
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
Press releaseApr 1, 4:05 PM ETGlobe Newswire
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
Press releaseMar 19, 4:05 PM ETGlobe Newswire
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
NewsFeb 26, 7:06 AM ET
Akebia Therapeutics Q4 Earnings Report: What Investors Need to Know
Press releaseFeb 26, 7:00 AM ETGlobe Newswire
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
NewsFeb 26, 6:11 AM ET
Earnings Scheduled For February 26, 2026
NewsFeb 25, 1:02 PM ET
Uncovering Potential: Akebia Therapeutics's Earnings Preview
NewsFeb 25, 7:00 AM ET
Where Akebia Therapeutics Stands With Analysts
NewsFeb 6, 4:00 PM ET
Breaking Down Akebia Therapeutics: 4 Analysts Share Their Views
NewsDec 1, 9:43 AM ETVandana Singh
Why Is Small-Cap Q32 Bio Stock Soaring On Monday?
Press releaseDec 1, 7:00 AM ETPRNewswire
Q32 Bio Sells Complement Inhibitor ADX-097
NewsNov 10, 12:07 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
Press releaseNov 10, 7:00 AM ETGlobe Newswire
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
NewsNov 7, 11:04 AM ET
An Overview of Akebia Therapeutics's Earnings
NewsOct 29, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsOct 29, 8:06 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsMay 8, 8:07 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
NewsMay 8, 4:33 AM ET
Earnings Scheduled For May 8, 2025
NewsMay 7, 11:03 AM ET
Insights Ahead: Akebia Therapeutics's Quarterly Earnings
NewsMar 20, 1:06 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsMar 20, 12:01 PM ETAvi Kapoor
Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase
NewsMar 19, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsMar 14, 1:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
Press releaseJan 13, 8:00 AM ETPRNewswire
Akebia Therapeutics Announces Multiple Positive Business Updates
Press releaseJan 2, 4:05 PM ETPRNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseDec 18, 8:00 AM ETPRNewswire
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Press releaseDec 3, 4:05 PM ETPRNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseDec 3, 7:00 AM ETPRNewswire
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis
Press releaseNov 25, 8:00 AM ETPRNewswire
Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
Press releaseNov 14, 8:00 AM ETPRNewswire
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease
Press releaseNov 12, 8:00 AM ETPRNewswire
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference
Press releaseNov 7, 7:00 AM ETPRNewswire
Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Western Digital, Applovin, Zillow Group And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

Akebia Therapeutics Q1 EPS $(0.03), Inline, Sales $53.544M Beat $51.668M Estimate

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors

Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026

Akebia Therapeutics Q4 Earnings Report: What Investors Need to Know

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

Earnings Scheduled For February 26, 2026

Uncovering Potential: Akebia Therapeutics's Earnings Preview

Where Akebia Therapeutics Stands With Analysts

Breaking Down Akebia Therapeutics: 4 Analysts Share Their Views

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Q32 Bio Sells Complement Inhibitor ADX-097

12 Health Care Stocks Moving In Monday's Intraday Session

Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

An Overview of Akebia Therapeutics's Earnings

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Earnings Scheduled For May 8, 2025

Insights Ahead: Akebia Therapeutics's Quarterly Earnings

12 Health Care Stocks Moving In Thursday's Intraday Session

Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Friday's Intraday Session

Akebia Therapeutics Announces Multiple Positive Business Updates

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights